Life sciences news
-
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
Tuesday January 12th 2021
Read more
-
Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
Tuesday December 22nd 2020
Read more
-
Mithra Announces Positive DSMB Safety Review and Continuation of its Phase III Clinical Program Donesta® in menopause
Wednesday December 16th 2020
Read more
-
Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
Thursday December 3rd 2020
Read more
-
reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
Thursday December 3rd 2020
Read more
-
Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial
Tuesday December 1st 2020
Read more
-
Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods
Tuesday November 17th 2020
Read more
-
First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
Tuesday November 10th 2020
Read more
-
Become a flanders.bio member
Your news here?
-
Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
Tuesday October 20th 2020
Read more
-
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
Friday October 16th 2020
Read more
-
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
Wednesday October 14th 2020
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
